Agios Pharmaceuticals (AGIO) closed at $29.41 on November 6, 2026, up 4.0% from the previous close, on volume of 1,224,973 shares (30-day average 1,266,669).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Call with Delta Hedge | 20-Nov-26 35 C +29,006 Stock | 821 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Bank of America Securities Sticks to Its Buy Rating for Agios Pharma (AGIO)
TipRanks (Fri, 6-Nov 7:59 AM ET)
TipRanks (Thu, 5-Nov 5:40 PM ET)
Agios Pharmaceuticals GAAP EPS of -$1.09 beats by $0.15, revenue of $55.39M beats by $3.79M
Seeking Alpha News (Thu, 5-Nov 6:43 AM ET)
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 6:30 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 4-Nov 6:00 PM ET)
Agios Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 12:38 PM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
TipRanks (Tue, 3-Nov 3:40 AM ET)
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Agios Pharma (AGIO)
TipRanks (Tue, 3-Nov 3:20 AM ET)
Globe Newswire (Fri, 30-Oct 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of November 6, 2026, AGIO stock price climbed to $29.41 with 1,224,973 million shares trading.
AGIO has a beta of 2.09, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.09 to the broad based SPY ETF.
AGIO has a market cap of $1.76 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $55 million in Revenue and -$1.09 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.16.
In the last 3 years, AGIO traded as high as $62.58 and as low as $20.40.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, VB, IWM, VBK.
AGIO has underperformed the market in the last year with a price return of -27.0% while the SPY ETF gained +10.8%. AGIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.9% and -20.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
AGIO support price is $27.10 and resistance is $29.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.
